IMNM
Immunome, Inc. NASDAQ Listed Oct 2, 2020$22.19
Mkt Cap $1.9B
52w Low $7.28
73.2% of range
52w High $27.65
50d MA $21.98
200d MA $17.82
P/E (TTM)
-9.3x
EV/EBITDA
-5.8x
P/B
3.1x
Debt/Equity
0.0x
ROE
-33.5%
P/FCF
-9.4x
RSI (14)
—
ATR (14)
—
Beta
2.14
50d MA
$21.98
200d MA
$17.82
Avg Volume
1.2M
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
665 Stockton Drive · Bothell, PA 19341 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -0.59 | -0.75 | -27.1% | 21.54 | +2.1% | +4.5% | -2.7% | -2.3% | -1.0% | +1.5% | — |
| Nov 6, 2025 | AMC | -0.57 | -0.65 | -14.0% | 15.50 | -0.3% | -1.7% | +6.1% | +13.0% | +12.5% | +6.5% | — |
| Aug 6, 2025 | AMC | -0.52 | -0.50 | +3.8% | 10.46 | +2.4% | -5.6% | -7.4% | -7.6% | -5.3% | -4.3% | — |
| May 12, 2025 | AMC | -0.66 | -0.52 | +21.2% | 7.94 | +5.4% | -0.4% | +0.4% | +0.8% | +1.5% | +0.9% | — |
| Mar 19, 2025 | AMC | -0.68 | -0.84 | -23.5% | 8.57 | -1.8% | +1.1% | -4.6% | -4.9% | -18.9% | -17.3% | — |
| Nov 13, 2024 | AMC | -0.60 | -0.78 | -30.0% | 11.59 | -0.2% | -3.9% | -14.6% | -18.6% | -19.0% | -19.5% | — |
| Aug 12, 2024 | AMC | -0.38 | -0.49 | -28.9% | 12.64 | +0.8% | +7.0% | +6.8% | +10.4% | +7.0% | +13.1% | — |
| May 14, 2024 | AMC | -0.80 | -0.34 | +57.5% | 14.72 | +1.4% | +0.5% | -2.2% | -6.0% | -6.2% | -7.3% | — |
| Mar 28, 2024 | AMC | -0.28 | -0.54 | -92.9% | 24.68 | +0.5% | -10.4% | -13.3% | -12.5% | -17.9% | -17.9% | — |
| Nov 9, 2023 | AMC | -0.17 | -0.36 | -111.8% | 8.56 | -1.4% | -5.5% | -3.7% | -6.3% | -7.1% | -7.4% | — |
| Aug 9, 2023 | AMC | -0.16 | -0.46 | -187.5% | 7.04 | +0.7% | +0.1% | +3.2% | +1.3% | +5.8% | +3.7% | — |
| May 5, 2023 | AMC | 0.59 | -0.35 | -159.3% | 5.40 | +0.9% | +6.7% | +15.7% | +16.7% | +17.8% | +26.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | Craig-Hallum | Maintains | Buy → Buy | — | $21.54 | $22.00 | +2.1% | +4.5% | -2.7% | -2.3% | -1.0% | +1.5% |
| Mar 4 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.54 | $22.00 | +2.1% | +4.5% | -2.7% | -2.3% | -1.0% | +1.5% |
| Jan 15 | Wedbush | Maintains | Outperform → Outperform | — | $20.76 | $20.61 | -0.7% | +10.1% | +7.9% | +15.0% | +19.8% | +24.4% |
| Dec 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.64 | $22.88 | +1.1% | +3.7% | -12.6% | -11.9% | -5.3% | -2.7% |
| Dec 16 | Guggenheim | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -12.6% | -11.9% | -5.3% | -2.7% |
| Dec 16 | Lake Street | Maintains | Buy → Buy | — | $22.64 | $22.88 | +1.1% | +3.7% | -12.6% | -11.9% | -5.3% | -2.7% |
| Nov 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $17.14 | $17.71 | +3.3% | +5.8% | +4.2% | +3.2% | +2.2% | +8.1% |
| Aug 25 | Guggenheim | Maintains | Buy → Buy | — | $10.30 | $10.30 | +0.0% | -3.7% | -1.4% | -3.4% | -3.9% | -7.7% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $10.46 | $10.71 | +2.4% | -5.6% | -7.4% | -7.6% | -5.3% | -4.3% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $8.57 | $8.42 | -1.8% | +1.1% | -4.6% | -4.9% | -18.9% | -17.3% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $8.57 | $8.42 | -1.8% | +1.1% | -4.6% | -4.9% | -18.9% | -17.3% |
| Mar 20 | Stephens & Co. | Maintains | Overweight → Overweight | — | $8.57 | $8.42 | -1.8% | +1.1% | -4.6% | -4.9% | -18.9% | -17.3% |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.59 | $11.57 | -0.2% | -3.9% | -14.6% | -18.6% | -19.0% | -19.5% |
| Oct 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.01 | $12.10 | +0.7% | +0.8% | +3.5% | +1.6% | +1.6% | -4.5% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.64 | $12.74 | +0.8% | +7.0% | +6.8% | +10.4% | +7.0% | +13.1% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $12.64 | $12.74 | +0.8% | +7.0% | +6.8% | +10.4% | +7.0% | +13.1% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $24.68 | $24.81 | +0.5% | -10.4% | -13.3% | -12.5% | -17.9% | -17.9% |
| Jan 23 | Wedbush | Maintains | Outperform → Outperform | — | $15.65 | $15.92 | +1.7% | -4.2% | -2.1% | +4.8% | +11.7% | +23.3% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.69 | $5.63 | -1.1% | -0.7% | -1.6% | -5.6% | -9.3% | -10.5% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $5.14 | $5.02 | -2.4% | +10.6% | +9.8% | +8.8% | +4.4% | +0.3% |
| Oct 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.85 | $23.30 | +2.0% | +2.6% | -2.5% | +0.2% | -3.9% | -0.9% |
| Oct 27 | Chardan Capital | Maintains | Buy → Buy | — | $12.20 | $12.49 | +2.4% | +2.5% | -5.7% | -5.3% | -7.0% | -10.0% |
No insider trades available.
Data updated apr 25, 2026 3:19pm
· Source: massive.com